Peregrine Pharmaceuticals (PPHM +82%) soars after the company says data on its experimental...


Peregrine Pharmaceuticals (PPHM +82%) soars after the company says data on its experimental cancer drug bavituximab was not completely compromised by errors in a mid-stage trial. An internal review found the errors to concern only the lowest dose and placebo arms of the study. This means the drug should be able to enter into a late-stage trial, and PPHM is preparing for discussions with the FDA. PPHM had been tight-lipped about the trial errors since being discovered in September, which had caused shares to plunge.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs